Neuroendocrine immunophenotype as predictor of clinical recurrence in 110 patients with prostate cancer

International Journal of Immunopathology and Pharmacology

Volumn 20, Issue 4, 2007, Pages 765-770

  Autorino, Riccardo ^a,d   Lamendola, M G ^a   De Luca, G ^a   De Sio, M ^a   Giugliano, F ^a   D'Armiento, M ^a   De Placido, S ^b   Conti, P ^c   Di Lorenzo, G ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d Clinica Urologia   (Italy)

Author keywords

Chromogranin A; Neuroendocrine differentiation; Prostate cancer; Radical prostatectomy

Indexed keywords

CHROMOGRANIN A; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BIOCHEMISTRY; CANCER RECURRENCE; CELL DIFFERENTIATION; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; LYMPH NODE; MALE; NEUROENDOCRINE SYSTEM; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; STAINING; TUMOR CELL; UNIVARIATE ANALYSIS;

EID: 37749041162     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200702000412     Document Type: Article

References (22)

1. Abbas A.K., A.H. Litchman and J.S. Pober. 1991. Immunity to tumours. In Cellular and molecular immunology, ed. W.B. Saunders. p. 335.
2. Deepak P., S. Kumar and A. Acharya. 2006. Heat shock proteins (HSP): future trends in cancer immunotherapy. Eur. J. Inflam. 4:1.
3. Kumar S., P. Deepak and A. Acharya. 2006. HSP70 modulates the enhanced production of reactive intermediate metabolites and a pro-inflammatory cytokine TNF-α expression in a T cell lymphoma. Eur. J. Inflam. 4:152.
4. Deepak P., S. Kumar and A. Acharya. 2007. IL-13 neutralization modulates function of type II polarized macrophages in vivo in a murine T-cell lymphoma. Eur. J. Inflam. 5:37.
5. Abrahamsson P.A. 1999. Neuroendocrine differentiation in prostatic carcinoma. Prostate 39:135.
6. Quek M.L., S. Daneshman and S. Rodrigo. 2006. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer. Urology 67: 1252.
7. Ather M.H. and F. Abbas. 2000. Prognostic significance of neuroendocrine differentiation in prostate cancer. Eur. Urol. 38:542.
8. Ahlgren G., K. Pedersen, S. Lundberg, G. Aus, J. Hugosson and P.A. Abrahamsson. 2000. Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. Urology 56:1015.
9. Amling C.L., E.J. Bergstralh, M.L. Blute, J.M. Slezak and H. Zincke. 2001. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J. Urol. 165:1151.
10. Bostwick D.G., J. Qian, A. Pacelli, H. Zincke, M. Blute and E.J. Bergstralh. 2002. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. J. Urol. 168:1211.
11. Kokubo H., Y. Yamada, Y. Nishio, H. Fukatsu, N. Honda and A. Nakagawa. 2005. Immunohistochemical study of chromogranin A in stage D2 prostate cancer. Urology 66:135.
12. Cohen R.J., G. Glezerson and Z. Haffejee. 1991. Neuro-endocrine cells: a new prognostic parameter in prostate cancer. Br. J. Urol. 68:258.
13. Allen F.J., D.J.J. van Velden and C.F. Heyns. 1995. Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer? Br. J. Urol. 75:751.
14. Aprikan A.G., C. Cordon-Cardo, W.R. Fair and V.E. Reuter. 1993. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 71:3952.
15. Krijnen J.L.M., J.F.T.A. Bogdanowicz, C.A. Seldenrijk, P.G.H. Mulder and T.H. van der Kwast. 1997. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J. Urol. 158:174.
16. Bonkhoff H., U. Stein and K. Remberger. 1994. Multidirectional differentiation in the normal, hyerplastic, and neoplastic human prostate: simultaneous demonstration of cell specific epithelial markers. Hum. Pathol. 25:42.
17. Ahlgren G., K. Pedersen, S. Ludeberg, G. Aus, J. Hugosson and P.A. Abrahamsson. 2000. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 42:274.
18. Van de Voorde W.M., A.A. Elgamal, H.P. Van Poppel, E.K. Verbeken, L.V. Baert and J.M. Lauweryns. 1994. Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies. Cancer 74:3164.
19. Weinstein M.H., A.W. Partin, R.W. Veltri and J.L. Epstein. 1996. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum. Pathol. 27:683.
20. Cohen M.K., D.A. Arber, K.S. Coffield, G.T. Keegan, J. McClintock and V.O. Speights. 1994. Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer 74:1899.
21. Theodorescu D., S.R. Border, J.C. Boyd et al. 1997. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 80:2109.
22. Pruneri G., S. Galli, R. Rossi et al. 1998. Chromogranin A and B and secretogranin in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. Prostate 34:113.